Outcome
HLH
RECURRENCE, REMISSION
Regarding patients who achieved remission, three received primary disease-specific treatment and one underwent pregnancy termination after remission of HLH. None of these four patients experienced HLH recurrence, and all survived until follow-up. Patient 7 and 8, who achieved remission after adding etoposide to high-dose ruxolitinib, also survived until follow-up. After a median follow-up of 159 days (IQR 25-242 days), two patients (patient 4 and 6) died, resulting in an estimated two-month overall survival rate of 75%. The survival curve was presented in The survival function of all 8 patients.